Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Published byΑνθούσα Καψής Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Critical signalling pathways involved in PDAC pathogenesis"— Presentation transcript:

1 Figure 1 Critical signalling pathways involved in PDAC pathogenesis
Figure 1 | Critical signalling pathways involved in PDAC pathogenesis. Critical signalling pathways associated with initiation and progression of pancreatic ductal adenocarcinoma (PDAC): from left to right, the Hedgehog (HH), PI3K/AKT, RAS/MAPK, and autophagy pathways. Each of these pathways can be exploited, independently or in combination, to develop unique treatment strategies. The figure highlights several nanomedicine and/or small-molecule agents, either FDA approved or in various stages of preclinical or clinical development, that are being pursued to inhibit and/or interfere with the pathways involved in PDAC, in order to better combat the disease. Adiseshaiah, P. P. et al. (2016) Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 1 Critical signalling pathways involved in PDAC pathogenesis"

Similar presentations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 3 Risk-adapted and response-adapted

Figure 3 Risk-adapted and response-adapted
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Volume 21, Issue 3, Pages (March 2012)

Volume 21, Issue 3, Pages (March 2012)
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google